Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free VYNE Stock Alerts

VYNE Therapeutics (VYNE) Competitors

VYNE Therapeutics logo
$0.65 0.00 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$0.65 0.00 (-0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VYNE vs. IBIO, BTMD, RLYB, JATT, and HRTX

Should you buy VYNE Therapeutics stock or one of its competitors? MarketBeat compares VYNE Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VYNE Therapeutics include iBio (IBIO), biote (BTMD), Rallybio (RLYB), JATT Acquisition (JATT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does VYNE Therapeutics compare to iBio?

iBio (NASDAQ:IBIO) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

iBio presently has a consensus target price of $5.00, suggesting a potential upside of 189.02%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iBio
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.13
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

In the previous week, iBio and iBio both had 1 articles in the media. VYNE Therapeutics' average media sentiment score of 1.89 beat iBio's score of 1.87 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
iBio Very Positive
VYNE Therapeutics Very Positive

7.9% of iBio shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

iBio has higher earnings, but lower revenue than VYNE Therapeutics. iBio is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iBio$400K214.87-$18.38M-$0.58N/A
VYNE Therapeutics$454K47.57-$26.48M-$0.38N/A

iBio has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. iBio's return on equity of -53.86% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
iBioN/A -53.86% -46.48%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

iBio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Summary

iBio beats VYNE Therapeutics on 9 of the 16 factors compared between the two stocks.

How does VYNE Therapeutics compare to biote?

VYNE Therapeutics (NASDAQ:VYNE) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

biote has a net margin of 8.29% compared to VYNE Therapeutics' net margin of -4,726.21%. biote's return on equity of -25.72% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-4,726.21% -70.42% -63.46%
biote 8.29%-25.72%15.12%

biote has a consensus target price of $2.75, indicating a potential upside of 64.67%. Given biote's stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
biote
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, biote has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

biote has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$454K47.57-$26.48M-$0.38N/A
biote$192.22M0.33$27.05M$0.443.80

In the previous week, biote had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for biote and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat biote's score of 0.93 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
VYNE Therapeutics Very Positive
biote Positive

Summary

biote beats VYNE Therapeutics on 13 of the 17 factors compared between the two stocks.

How does VYNE Therapeutics compare to Rallybio?

Rallybio (NASDAQ:RLYB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Rallybio has higher revenue and earnings than VYNE Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K98.97-$8.98M-$4.34N/A
VYNE Therapeutics$454K47.57-$26.48M-$0.38N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Rallybio and Rallybio both had 1 articles in the media. VYNE Therapeutics' average media sentiment score of 1.89 beat Rallybio's score of 1.87 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Rallybio Very Positive
VYNE Therapeutics Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Rallybio has a beta of -0.89, indicating that its stock price is 189% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

Rallybio has a net margin of -911.07% compared to VYNE Therapeutics' net margin of -4,726.21%. Rallybio's return on equity of -55.79% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -55.79% -51.48%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

Summary

Rallybio beats VYNE Therapeutics on 8 of the 13 factors compared between the two stocks.

How does VYNE Therapeutics compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

JATT Acquisition has higher earnings, but lower revenue than VYNE Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
VYNE Therapeutics$454K47.57-$26.48M-$0.38N/A

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, JATT Acquisition and JATT Acquisition both had 1 articles in the media. VYNE Therapeutics' average media sentiment score of 1.89 beat JATT Acquisition's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
JATT Acquisition Neutral
VYNE Therapeutics Very Positive

JATT Acquisition has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. JATT Acquisition's return on equity of -49.58% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
VYNE Therapeutics -4,726.21%-70.42%-63.46%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

JATT Acquisition beats VYNE Therapeutics on 5 of the 9 factors compared between the two stocks.

How does VYNE Therapeutics compare to Heron Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Heron Therapeutics has higher revenue and earnings than VYNE Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$454K47.57-$26.48M-$0.38N/A
Heron Therapeutics$154.90M0.53-$20.19M-$0.18N/A

In the previous week, Heron Therapeutics had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat Heron Therapeutics' score of 1.33 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
VYNE Therapeutics Very Positive
Heron Therapeutics Positive

Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 474.05%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Heron Therapeutics
2 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Heron Therapeutics has a net margin of -20.53% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-4,726.21% -70.42% -63.46%
Heron Therapeutics -20.53%-7,747.30%-8.94%

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Summary

Heron Therapeutics beats VYNE Therapeutics on 10 of the 16 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYNE vs. The Competition

Export
MetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.62M$3.04B$6.85B$12.20B
Dividend YieldN/A1.87%2.66%6.22%
P/E Ratio-1.7019.6726.0424.36
Price / Sales47.57349.52550.39103.01
Price / CashN/A56.8529.0936.93
Price / Book0.784.2510.986.49
Net Income-$26.48M$64.45M$3.57B$336.61M
7 Day Performance-0.38%4.17%3.06%0.90%
1 Month Performance-5.04%1.44%0.72%-0.36%
1 Year Performance-54.40%34.07%36.82%31.26%

VYNE Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYNE
VYNE Therapeutics
1.4775 of 5 stars		$0.65
-0.1%		N/A-54.3%$21.62M$454KN/A30
IBIO
iBio
3.6571 of 5 stars		$1.65
-5.2%		$5.00
+203.0%		N/A$86.44M$400KN/A100
BTMD
biote
4.181 of 5 stars		$2.15
-4.4%		$2.75
+27.9%		-57.4%$84.56M$192.22M4.89194
RLYB
Rallybio
1.3511 of 5 stars		$15.70
-1.4%		N/A+501.3%$84.40M$860KN/A40
JATT
JATT Acquisition
N/A$10.40
-3.3%		N/A+893.8%$83.46MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VYNE) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel